Résztvevőt keres itt: Kína1. fázis
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
A legfontosabb adatok
- Ki végzi
- Guangdong Hengrui Pharmaceutical Co., Ltd
- Hol
- Wuhan (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 10 fő, tervezett
- Kezdés
- 2025. nov. 12.
- Várható befejezés
- 2026. nov.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- SHR-2173 Injection
- A regiszteradat frissítve
- 2026. május 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with primary immune thrombocytopenia (ITP), a condition with low blood platelets. It tests multiple injections under the skin of SHR-2173.
- Életkor
- 18 years or older
- Nem
- All sexes can join
- A betegség stádiuma
- Primary ITP diagnosed at least 3 months before screening. Platelet count below 30×10⁹/L, with a need for treatment. Stable condition with WHO bleeding grade 0-1.
- Korábbi kezelés
- Must have had corticosteroids before. The last ITP treatment stopped working, did not work, the disease came back, or it was not tolerated. Cannot have had SHR-2173 or spleen removal before.
- Biomarker vagy leletérték
- Platelet count below 30×10⁹/L. Normal prothrombin time and activated partial thromboplastin time (blood clotting tests).
A részvétel fő kizáró okai
- ITP caused by another disease, or autoimmune hemolytic anemia
- Blood clots within 12 months, clotting disorders, or blood thinners (except low-dose acetylsalicylic acid)
- Life-threatening bleeding now, or active infection needing treatment
- Myelodysplastic syndrome or cancer within 5 years, with some exceptions
- Earlier stem cell or organ transplant, spleen removal, pregnancy or breastfeeding
A regiszter feltételei, szó szerint
Mind a 27 feltétel megnézéseKevesebb
Ki vehet részt
- Participants must fully understand the trial content, procedures, and potential adverse reactions, and voluntarily sign a written informed consent form (ICF)
- Age at signing the ICF must be ≥ 18 years (including the boundary value), regardless of gender
- Confirmed diagnosis of primary ITP for at least 3 months at screening
- Previous treatment with corticosteroids
- At the last ITP treatment, participants experienced loss of remission, no remission, relapse after remission, or intolerance
- Platelet count <30×10⁹/L at screening with clinical assessment indicating treatment necessity
- Participants must have adequate organ function
- Clinically stable condition with World Health Organization (WHO) bleeding scale grade 0-1
- Female participants of childbearing potential or male participants with fertile partners must refrain from sperm/ova donation from ICF signing until 12 weeks after last dose and agree to protocol-specified contraceptive measures
Ki nem vehet részt
- Diagnosis of secondary thrombocytopenia or concomitant autoimmune hemolytic anemia
- Received immunosuppressants (other than corticosteroids) such as Janus kinase [JAK] inhibitors or Bruton tyrosine kinase [BTK] inhibitors within either 5 times the drug elimination half-life or 14 days prior to the first infusion of SHR-2173 (whichever is longer)
- Previous treatment with SHR-2173
- Screening prothrombin time or activated partial thromboplastin time outside the normal range; concurrent coagulation disorders and/or receiving antiplatelet or anticoagulant medications (e.g., warfarin, clopidogrel, novel oral anticoagulants), except for low-dose acetylsalicylic acid
- History of any thrombotic or embolic events within 12 months prior to the first administration, or clinical symptoms and history suggesting thrombophilia
- Received live or attenuated live vaccines within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
- Received live or attenuated live vaccines within 8 weeks prior to the first administration of SHR-2173, or planned to receive live/attenuated vaccinations during the trial
- Diagnosis of myelodysplastic syndrome; history of or current malignancy within 5 years prior to screening (except for cured non-melanoma skin cancer, in situ carcinoma [e.g., cervical, breast, bladder, prostate cancer], and cancers in complete remission for at least 5 years with no evidence of recurrence)
- Previous splenectomy
- Previous allogeneic stem cell or organ transplantation (except for corneal transplantation ≥ 3 months prior to screening); known or suspected history of immunosuppression
- Planned surgery during the dosing period
- Concurrent participation in other investigational studies within either 30 days prior to enrollment or 5 half-lives of the investigational drug (whichever is longer)
- Current life-threatening bleeding (related to thrombocytopenia) or expected to require emergency treatment within one week after randomization
- Active viral, bacterial, or other infections (including tuberculosis [TB]) requiring systemic treatment at screening, or SARS-CoV-2 infection during screening, or history of clinically significant recurrent infections
- Any severe and/or unstable pre-existing medical, psychiatric, or other conditions that the investigator judges may interfere with patient safety, obtaining informed consent, or compliance with study procedures
- Allergic constitution (e.g., allergies to two or more drugs, foods, or pollens) or known hypersensitivity (immediate or delayed) or atopic reactions to the study drug (including excipients, monoclonal antibodies)
- Received platelet transfusion, whole blood transfusion, plasma exchange, or any other emergency treatment drugs within 14 days prior to the first infusion of SHR-2173
- Females who are lactating or pregnant (positive serum or urine β-human chorionic gonadotropin [hCG]) at screening or on Day 1 of Week 1 prior to administration
Helyszínek itt: Kína
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, KínaContact: Heng Mei (principal investigator)Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Evaluate the safety and tolerance of multiple subcutaneous injections of SHR-2173 in ITP patients
A vizsgálat csoportja
- SHR-2173 InjectionA vizsgált kezelés
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase I Study Evaluating the Safety, Efficacy, Pharmacokinetics and Pharmacokinetics of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. május 28.